The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL)...read more
Lyell Immunopharma, a preclinical biotech developing T cell therapies for solid tumors, raised $425 million by offering 25 million shares at $17, the midpoint of the range of $16 to $18. At pricing, the company commands a fully diluted market value of $4.7...read more
Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise...read more
Lyell Immunopharma, a preclinical biotech developing T cell therapies for solid tumors, announced terms for its IPO on Wednesday. The South San Francisco, CA-based company plans to raise $425 million by offering 25 million shares at a price range of $16 to...read more
US IPO Weekly Recap: IPO market in full swing as biotechs lead a 16 IPO week
The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL)...read more
Preclinical solid tumor biotech Lyell Immunopharma prices IPO at $17 midpoint
Lyell Immunopharma, a preclinical biotech developing T cell therapies for solid tumors, raised $425 million by offering 25 million shares at $17, the midpoint of the range of $16 to $18. At pricing, the company commands a fully diluted market value of $4.7...read more
US IPO Week Ahead: Biotechs and software lead a 15 IPO week
Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise...read more
Preclinical solid tumor biotech Lyell Immunopharma sets terms for $425 million IPO
Lyell Immunopharma, a preclinical biotech developing T cell therapies for solid tumors, announced terms for its IPO on Wednesday. The South San Francisco, CA-based company plans to raise $425 million by offering 25 million shares at a price range of $16 to...read more